About SimBioSys
SimBioSys is a TechBio company that combines artificial intelligence, spatial biophysics, and data science to individualize cancer therapy and improve patient outcomes. Founded in 2017 by Dr. Joe Peterson, Dr. John Cole, and Tushar Pandey at the University of Illinois, the company emerged from a National Cancer Institute-funded research project focused on novel cancer modeling approaches. SimBioSys has developed a comprehensive platform that addresses tumor heterogeneity by analyzing tumors in their entirety, moving beyond traditional biopsies or 2D pathology slides. Their flagship product, TumorSight Viz, is FDA-cleared for breast cancer surgical planning and transforms DCE-MRI studies into visually detailed, interactive 3D representations that enable precise measurements of tumor volume and distances to anatomical features. The company's technology leverages Convolutional Neural Networks to automatically segment tumors and surrounding tissues, creating digital twins that capture the physical, chemical, and biological characteristics of tumors at tissue and cellular levels. SimBioSys serves breast surgeons, oncologists, and cancer centers with both clinical and research solutions spanning the entire continuum of patient care, from visualization and surgical planning to recurrence risk prediction and treatment response modeling. The company has grown to over 20 employees and maintains research collaborations with leading institutions including Mayo Clinic, UCLA, and the University of Chicago, with backing from premier healthtech venture capital firms and Mayo Clinic as an investor.
Mission & Story
Mission
Redefine precision medicine, revolutionize patient care, and ultimately defeat cancer
Founding Story
In 2017, Dr. Joe Peterson and Dr. John Cole were working together in a lab at the University of Illinois developing a novel approach to cancer modeling with a newly funded National Cancer Institute grant. They identified a fundamental gap in oncology decision-making that could be bridged through biophysical modeling and AI-driven precision medicine. Their vision was to revolutionize cancer care through a purely software-based solution providing deeper insights into tumor biology. Tushar Pandey joined shortly after, and together they founded SimBioSys.
Clinical Focus
Medical conditions and clinical areas addressed by SimBioSys.
Who It Serves
Milestones & Awards
Recent Milestones
FDA clearance for TumorSight Viz. Featured ABC News case study. Growing commercial presence at top cancer centers. Expansion to 20+ employees.
Key Partnerships
Social & Media
Company Details
- Founded
- 2017
- Headquarters
- Champaign, IL, USA
- Employees
- 11-50
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.